ERAS Measures** | Intervention Period Relative to Baseline Period | Post Intervention Period Relative to Intervention Period |
|---|
| | Estimate | 95% CI | Estimate | 95% CI |
|---|
Preemptive Analgesia | 8.29 | 6.49–10.59 | 0.84 | 0.63–1.12 |
Antiemetics Use | 1.35 | 0.92–1.99 | 0.80 | 0.54–1.18 |
Intraop Fluid Management | 1.58 | 1.25–1.99 | 0.80 | 0.64–1.01 |
Short Acting Narcotics | 0.86 | 0.82–0.90 | 1.02 | 0.97–1.06 |
Long Acting Narcotics | 0.91 | 0.82–1.00 | 0.98 | 0.89–1.08 |
- *These results are based on regression models that controlled for the following covariates: age, heart rate, systolic blood pressure, BMI category (normal, overweight, obese, unknown), ASA category (healthy, mild, sever, missing), hysterectomy type (laparoscopic, vaginal, debulk-open, plain open), section (oncology, endocrinology, MIGS, pelvic medicine, specialist), ERAS Measures (in each ERAS model, we included the other remaining four. For example, when we assess use of short acting narcotics, we controlled for use of long acting narcotics, preemptive analgesia, antiemetics use and intraop fluid administration)
- **The first three metrics are measured as binary (yes/no) outcomes and we used logistic regression to model them. The two last two are measured as a continuous outcome in microgram/kg and are modeled using generalized linear model with log link and gamma distribution
- *** Results show, except for use of antiemetics, which was already high during the baseline period, the other four ERAS measures have significantly improved in the intervention period (relative to baseline period) and these improvements were sustained during the post-intervention period
